Iron Formulations and Gastrointestinal Tolerability

Evidence-Based Formulation Hierarchy for GI Tolerability

Ferric maltol is recommended for patients with previous intolerance to traditional iron salts, demonstrating GI side effects comparable to placebo in clinical trials, with the British Society of Gastroenterology guidelines highlighting its preferred adverse event profile 1, 2
In patients with inactive inflammatory bowel disease and moderate iron deficiency anemia, 12 weeks of ferric maltol normalized hemoglobin in 63-66% of cases with overall rates of treatment cessation comparable to placebo 1

Once-daily dosing significantly reduces GI side effects compared to divided doses while maintaining similar iron absorption, according to the British Society of Gastroenterology 1, 2
Limit elemental iron to no more than 100 mg per day in patients with GI sensitivity, particularly those with inflammatory bowel disease, as recommended by the European Crohn’s and Colitis Organisation 3, 2
Alternate-day dosing may improve fractional iron absorption and reduce side effects, though this approach requires further validation before routine implementation, as suggested by the American Gastroenterological Association 1, 2

Take iron at bedtime to potentially reduce awareness of gastrointestinal side effects, as recommended by the American Society of Nephrology 4, 2
Start with lower doses and gradually increase to the target dose to improve tolerance, according to the Kidney Disease: Improving Global Outcomes guidelines 4, 2
Add vitamin C (80-500 mg) to enhance absorption, potentially allowing lower iron doses, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 2, 5
Avoid tea or coffee within one hour of iron administration, as these inhibit absorption, according to the European Food Safety Authority 2, 6

Consider IV iron as first-line treatment in patients with clinically active inflammatory bowel disease, previous intolerance to oral iron despite formulation changes, hemoglobin below 10 g/dL, pronounced disease activity, or need for erythropoiesis-stimulating agents, as recommended by the European Crohn’s and Colitis Organisation and the American Gastroenterological Association 3, 1, 2
IV iron delivers faster response rates and is safer than oral iron in most patients, with several safe IV preparations now available, according to the American Society of Nephrology 3

Iron polysaccharide offers no advantage over ionic iron salts despite common perception—it is no better tolerated and may be less effective, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 4, 2
Unabsorbed oral iron can worsen inflammatory bowel disease through generation of reactive oxygen species, potentially exacerbating symptoms, according to the European Crohn’s and Colitis Organisation 3